How Long COVID develops is still largely unknown. New molecular connections are revealed in a recent study led by the Centre for Individualised Infection Medicine (CiiM). Using their approach of examining different molecular levels within individual cells, the researchers identified a specific condition in immune cells that was directly associated with elevated inflammation markers, fatigue, and respiratory problems in patients with Long COVID. The study was published in the journal Nature Immunology. The CiiM is a joint institution of the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH).

A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the drug-metabolising enzymes CYP2C19 and CYP2D6 significantly affect how drugs are processed in the human body. These results emphasise the need to look beyond common pharmacogenetic markers to improve the precision of personalised drug therapy.

Americans believe that the family as a whole—especially a spouse or partner—is responsible for caring for an older adult.

Garadacimab for hereditary angioedema: hint of a considerable added benefit

An indirect comparison has shown a sharp decline in the monthly rate of attacks, as well as other advantages. However, it remains incomprehensible why drug manufacturers continue to test their drugs against placebo in this therapeutic indication.

Two confirmed cases of Nipah virus disease have been reported in West Bengal, India. Based on current information, the risk of infection for people from Europe travelling to or residing in the area is assessed as very low.